Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells.

Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells.

Cancer prevention and therapy in HIV-1-infected patients will play an important role in future. The non-nucleoside reverse transcriptase inhibitors (NNRTI) Efavirenz and Nevirapine are cytotoxic against cancer cells in vitro. As other NNRTIs have not been studied so far, all clinically used NNRTIs w...

Full description

Bibliographic Details
Main Authors:	Markus Hecht, Sonja Erber, Thomas Harrer, Hartwig Klinker, Thomas Roth, Hans Parsch, Nora Fiebig, Rainer Fietkau, Luitpold V Distel
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4473268?pdf=render

Similar Items

Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models
by: Mastan SK, et al.
Published: (2009-10-01)

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
by: George W Rutherford, et al.
Published: (2016-01-01)

HIV Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz Reduces Neural Stem Cell Proliferation in Vitro and in Vivo
by: Jingji Jin, et al.
Published: (2016-11-01)

Palbociclib Induces Senescence in Melanoma and Breast Cancer Cells and Leads to Additive Growth Arrest in Combination With Irradiation
by: Tina Jost, et al.
Published: (2021-10-01)

Dual mTOR/DNA-PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential
by: Felix Bürkel, et al.
Published: (2020-12-01)

Senescence Induction by Combined Ionizing Radiation and DNA Damage Response Inhibitors in Head and Neck Squamous Cell Carcinoma Cells
by: Clara Dobler, et al.
Published: (2020-09-01)

Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz
by: Maryam A. Jordaan, et al.
Published: (2020-08-01)

Development of reverse phase high-performance liquid chromatographic method for the estimation of HIV non-nucleoside reverse transcriptase inhibitor drug efavirenz in the rat brain
by: Smita Prakash Kakad, et al.
Published: (2021-01-01)

Differences in and Prognostic Value of Quality of Life Data in Rectal Cancer Patients with and without Distant Metastases
by: Fabian Frank, et al.
Published: (2020-12-01)

Baseline Quality of Life of Physical Function Is Highly Relevant for Overall Survival in Advanced Rectal Cancer
by: Tim Fitz, et al.
Published: (2022-01-01)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
by: Stephanie Jonuscheit, et al.
Published: (2021-05-01)

Increase in non-professional phagocytosis during the progression of cell cycle.
by: Alexander Hofmann, et al.
Published: (2021-01-01)

CD8+ and Regulatory T cells Differentiate Tumor Immune Phenotypes and Predict Survival in Locally Advanced Head and Neck Cancer
by: Alessia Echarti, et al.
Published: (2019-09-01)

Role of tumor cell senescence in non-professional phagocytosis and cell-in-cell structure formation
by: Dorian Gottwald, et al.
Published: (2020-11-01)

PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts
by: Verena Weigert, et al.
Published: (2020-08-01)

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors.
by: Esnouf, R, et al.
Published: (1995)

Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
by: Murugesan Vanangamudi, et al.
Published: (2023-09-01)

Current scenario on non-nucleoside reverse transcriptase inhibitors (2018-present)
by: Cui Deng, et al.
Published: (2022-12-01)

Lipidic strategy for improving bioavailability of nucleoside HIV reverse transcriptase inhibitor
by: N. S. Shastina, et al.
Published: (2011-04-01)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
by: Valeria Famiglini, et al.
Published: (2016-02-01)

Cell-in-cell phenomenon: leukocyte engulfment by non-tumorigenic cells and cancer cell lines
by: Mareike F. Bauer, et al.
Published: (2021-07-01)

Influence of alectinib and crizotinib on ionizing radiation - in vitro analysis of ALK/ROS1-wildtype lung tissue cells
by: Tina Jost, et al.
Published: (2022-05-01)

Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
by: Ren, J, et al.
Published: (2000)

FEN1 Inhibition as a Potential Novel Targeted Therapy against Breast Cancer and the Prognostic Relevance of FEN1
by: Johanna Berfelde, et al.
Published: (2024-02-01)

The Effect of Xevinapant Combined with Ionizing Radiation on HNSCC and Normal Tissue Cells and the Impact of Xevinapant on Its Targeted Proteins cIAP1 and XIAP
by: Julia Fleischmann, et al.
Published: (2023-06-01)

The Application of Prodrugs as a Tool to Enhance the Properties of Nucleoside Reverse Transcriptase Inhibitors
by: Lívia da Rocha Fernandes, et al.
Published: (2023-11-01)

Nucleoside Analog Reverse-Transcriptase Inhibitors in Membrane Environment: Molecular Dynamics Simulations
by: Anna Stachowicz-Kuśnierz, et al.
Published: (2023-08-01)

The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance.
by: Meytal Galilee, et al.
Published: (2018-01-01)

HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors
by: Nicolas Tardiota, et al.
Published: (2024-01-01)

Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study
by: A. V. Kravchenko, et al.
Published: (2018-07-01)

HEPT: From an investigation of lithiation of nucleosides towards a rational design of non-nucleoside reverse transcriptase inhibitors of HIV-1
by: Tanaka, H, et al.
Published: (1999)

Rate of individuals with clearly increased radiosensitivity rise with age both in healthy individuals and in cancer patients
by: Barbara Schuster, et al.
Published: (2018-05-01)

In Vitro Analysis of Superparamagnetic Iron Oxide Nanoparticles Coated with APTES as Possible Radiosensitizers for HNSCC Cells
by: Clara Emer, et al.
Published: (2023-01-01)

Idelalisib may have the potential to increase radiotherapy side effects
by: Thomas Gryc, et al.
Published: (2017-06-01)

2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
by: Chan, J, et al.
Published: (2001)

Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
by: Ren, J, et al.
Published: (2008)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
by: Daniel M. Himmel, et al.
Published: (2020-06-01)

Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors
by: Peter V. Coveney, et al.
Published: (2012-07-01)

Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years
by: Chunlin Zhuang, et al.
Published: (2020-06-01)

Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
by: Nicolas Sluis-Cremer, et al.
Published: (2013-11-01)